共 79 条
- [1] Jackson S.(1997)The patient with overactive bladder —symptoms and quality of life issues Urology 50 18-22
- [2] Johannesson M.(1997)Willingness to pay for reduced incontinence symptoms Br J Urol 80 557-62
- [3] O’Connor R.M.(1999)Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine BJU Int 83 583-90
- [4] Kobelt G.(1999)The overactive bladder: an overview for primary care health providers Int J Fertil Womens Med 44 56-66
- [5] Kobelt G.(1988)Current concepts in the treatment of disorders of micturition Drugs 35 477-94
- [6] Kirchberger I.(1997)The overactive bladder: pharmacologic basis of drug treatment Urology 50 74-84
- [7] Malone-Lee J.(1995)Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging 6 243-62
- [8] Wein A.J.(1999)Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder Int Urogynecol J Pelvic Floor Dysfunct 10 283-9
- [9] Rovner E.S.(1998)Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride J Am Geriatr Soc 46 8-13
- [10] Andersson K.-E.(1997)Tolterodine —a new bladder-selective antimuscarinic agent Eur J Pharmacol 327 195-207